Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Tuberculosis | Research article

Effect of different interventions for latent tuberculosis infections in China: a model-based study

Authors: Zexuan Wen, Tao Li, Wenlong Zhu, Wei Chen, Hui Zhang, Weibing Wang

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Tuberculosis (TB) has a serious impact on people’s health. China is one of 30 countries that has a high TB burden. As the currently decreasing speed of the incidence of TB, the WHO’s goal of “End TB Strategy” is hard to achieve by 2035. As a result, a SEIR model that determines the impact of different tuberculosis preventive treatments (TPTs) in different age groups, and the effect of different interventions on latent TB infections (LTBIs) in China is developed.

Methods

A Susceptible-Exposed-Infectious-Recovered (SEIR) model was established. Goodness-of-fit tests were used to assess model performance. Predictive analysis was used to assess the effect of different interventions on LTBIs and achieving the goals of the “End TB Strategy”.

Results

The Chi-square test indicated the model provided a good statistical fit to previous data on the incidence of TB (χ2 = 0.3085, p > 0.999). The 1HP treatment regimen (daily rifapentine + isoniazid for 4 weeks) was most effective in reducing the number of TB cases by 2035. The model indicated that several strategies could achieve the 2035 target of the “End TB Strategy”: completion of active case finding (ACF) for LTBI and TPT nation-wide within 5 years; completion of ACF for LTBIs and TPT within 2 years in high-incidence areas; completion of TPT in the elderly within 2 years; or introduction of a new vaccine in which the product of annual doses and vaccine efficiency in the three age groups above 14 years old reached 10.5 million.

Conclusion

The incidence of TB in China declined gradually from 2005 to 2019. Implementation of ACF for LTBIs and TPT nation-wide or in areas with high incidence, in the elderly, or administration of a new and effective vaccine could greatly reduce the number of TB cases and achieve the 2035 target of the “End TB Strategy” in China.
Appendix
Available only for authorised users
Literature
2.
go back to reference China Nb. China statistical yearbook 2020. China Statistics Publishing House; 2020. China Nb. China statistical yearbook 2020. China Statistics Publishing House; 2020.
4.
go back to reference World Health Organization. Global tuberculosis report 2020. Geneva: WHO; 2020. World Health Organization. Global tuberculosis report 2020. Geneva: WHO; 2020.
5.
go back to reference Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33(5):956–73.CrossRef Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009;33(5):956–73.CrossRef
6.
go back to reference Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–247. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–247.
7.
go back to reference WHO consolidated guidelines on tuberculosis. Module 1, Module 1. Geneva: WHO; 2020. Accessed 1 Mar 2021. WHO consolidated guidelines on tuberculosis. Module 1, Module 1. Geneva: WHO; 2020. Accessed 1 Mar 2021.
8.
go back to reference He Y, Zhang H, Xin H, Gao L. Application of tuberculin skin test and its optimization. Chin J Anti-TB. 2021;43(03):204–10. He Y, Zhang H, Xin H, Gao L. Application of tuberculin skin test and its optimization. Chin J Anti-TB. 2021;43(03):204–10.
9.
go back to reference Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060–7.CrossRef Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060–7.CrossRef
10.
go back to reference Harris RC, Sumner T, Knight GM, Evans T, Cardenas V, Chen C, et al. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. Lancet Glob Health. 2019;7(2):e209–18.CrossRef Harris RC, Sumner T, Knight GM, Evans T, Cardenas V, Chen C, et al. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study. Lancet Glob Health. 2019;7(2):e209–18.CrossRef
11.
go back to reference Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA. 2009;106(33):13980–5.CrossRef Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA. 2009;106(33):13980–5.CrossRef
12.
go back to reference Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci USA. 2014;111(43):15520–5.CrossRef Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci USA. 2014;111(43):15520–5.CrossRef
13.
go back to reference Dye C, Watt CJ, Bleed DM, Williams BG. What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb). 2003;83(1–3):35–43.CrossRef Dye C, Watt CJ, Bleed DM, Williams BG. What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb). 2003;83(1–3):35–43.CrossRef
14.
go back to reference Ozcaglar C, Shabbeer A, Vandenberg SL, Yener B, Bennett KP. Epidemiological models of Mycobacterium tuberculosis complex infections. Math Biosci. 2012;236(2):77–96.CrossRef Ozcaglar C, Shabbeer A, Vandenberg SL, Yener B, Bennett KP. Epidemiological models of Mycobacterium tuberculosis complex infections. Math Biosci. 2012;236(2):77–96.CrossRef
15.
go back to reference Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;380(11):1001–11.CrossRef Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;380(11):1001–11.CrossRef
16.
go back to reference Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11–20.CrossRef Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11–20.CrossRef
17.
go back to reference Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–9.CrossRef Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–9.CrossRef
18.
go back to reference TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRef TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRef
19.
go back to reference Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, et al. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med. 2016;14:45.CrossRef Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, et al. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med. 2016;14:45.CrossRef
20.
go back to reference Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.CrossRef Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.CrossRef
21.
go back to reference Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, et al. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis. 2018;18(1):587.CrossRef Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, et al. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis. 2018;18(1):587.CrossRef
22.
go back to reference Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.CrossRef Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.CrossRef
23.
go back to reference Soetaert K, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve. J Stat Softw. 2010;33(9):1–25.CrossRef Soetaert K, Petzoldt T, Setzer RW. Solving differential equations in R: package deSolve. J Stat Softw. 2010;33(9):1–25.CrossRef
24.
go back to reference Expert consensus on screening and preventive treatment of latent Mycobacterium tuberculosis infection in children. Chin J Tuberc Respir Dis. 2020;43:345–9. Expert consensus on screening and preventive treatment of latent Mycobacterium tuberculosis infection in children. Chin J Tuberc Respir Dis. 2020;43:345–9.
25.
go back to reference Wang W-B, Zhang H, Petzold M, Zhao Q, Xu B, Zhao G-M. Cost-effectiveness of the Health X Project for tuberculosis control in China. Int J Tuberc Lung Dis. 2014;18(8):939–45.CrossRef Wang W-B, Zhang H, Petzold M, Zhao Q, Xu B, Zhao G-M. Cost-effectiveness of the Health X Project for tuberculosis control in China. Int J Tuberc Lung Dis. 2014;18(8):939–45.CrossRef
28.
go back to reference Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429–39.CrossRef Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429–39.CrossRef
29.
go back to reference Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013;13(10):852–8.CrossRef Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013;13(10):852–8.CrossRef
30.
go back to reference Durovni B, Cavalcante S. Preventive therapy for HIV-associated tuberculosis. Curr Opin HIV AIDS. 2018;13(6):507–11.CrossRef Durovni B, Cavalcante S. Preventive therapy for HIV-associated tuberculosis. Curr Opin HIV AIDS. 2018;13(6):507–11.CrossRef
31.
go back to reference Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28-37.CrossRef Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28-37.CrossRef
32.
go back to reference Wang Y, Wang W, Li T, Chen S, Wang Y, Chen W, et al. TB burden prediction under different diagnostic scenarios, a dynamic modeling study. Chin J Epidemiol. 2020;41:580–4. Wang Y, Wang W, Li T, Chen S, Wang Y, Chen W, et al. TB burden prediction under different diagnostic scenarios, a dynamic modeling study. Chin J Epidemiol. 2020;41:580–4.
33.
go back to reference Liu S, Bi Y, Liu Y. Modeling and dynamic analysis of tuberculosis in mainland China from 1998 to 2017: the effect of DOTS strategy and further control. Theor Biol Med Model. 2020;17(1):6.CrossRef Liu S, Bi Y, Liu Y. Modeling and dynamic analysis of tuberculosis in mainland China from 1998 to 2017: the effect of DOTS strategy and further control. Theor Biol Med Model. 2020;17(1):6.CrossRef
34.
go back to reference Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 2016;4(11):e806–15.CrossRef Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 2016;4(11):e806–15.CrossRef
35.
go back to reference Li B-Y, Shi W-P, Zhou C-M, Zhao Q, Diwan VK, Zheng X-B, et al. Rising challenge of multidrug-resistant tuberculosis in China: a predictive study using Markov modeling. Infect Dis Poverty. 2020;9(1):65.CrossRef Li B-Y, Shi W-P, Zhou C-M, Zhao Q, Diwan VK, Zheng X-B, et al. Rising challenge of multidrug-resistant tuberculosis in China: a predictive study using Markov modeling. Infect Dis Poverty. 2020;9(1):65.CrossRef
36.
go back to reference Liu C, Yan X. Advances in clinical application research of mycobacterium vaccae on treatment of tuberculosis. Electron J Emerg Infect Dis. 2020;5:274–6. Liu C, Yan X. Advances in clinical application research of mycobacterium vaccae on treatment of tuberculosis. Electron J Emerg Infect Dis. 2020;5:274–6.
38.
go back to reference Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum Vaccin Immunother. 2016;12(11):2813–32.CrossRef Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum Vaccin Immunother. 2016;12(11):2813–32.CrossRef
Metadata
Title
Effect of different interventions for latent tuberculosis infections in China: a model-based study
Authors
Zexuan Wen
Tao Li
Wenlong Zhu
Wei Chen
Hui Zhang
Weibing Wang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07465-5

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.